The need to improve treatment and care for people with blood cancers like myeloma, and the work of Myeloma UK, has been highlighted in the first report by Westminster’s cross-party group on blood cancer.
Patients in England and Wales will now be able to access the new myeloma treatment, daratumumab (Darzalex®) on the NHS, after the drug approval body the National Institute for Health and Care Excellence (NICE) approved it for use.
The results from this trial show that antibiotic prophylaxis with levofloxacin may improve the quality of life and outcomes of newly diagnosed myeloma patients by reducing the risk of infection and early death, without increasing the risk of developing antibiotic resistance and hospital-acquired infections.
CAR-T cell therapy (adoptive T cell transfer) is an exciting area of research and represents an entirely new way of […]
Highlights from the American Society of Hematology (ASH) conference 2017 being attended by Myeloma UK Chief Executive Rosemarie Finley and Director of Research, Dr Simon Ridley.
A new patient preference study has been published in The Oncologist, providing insight into how myeloma patients rationalise treatments.
Myeloma patients in the UK are being invited to take part in a study that is testing a new questionnaire which aims to support patients and their clinicians in discussing, addressing and better recording quality of life issues that matter patients.
Myeloma UK has launched MUK nine, the first UK-wide trial using state-of-the-art genetic techniques to ‘stratify’ treatment for so-called high-risk myeloma patients.
Patients in Scotland will now be able to access the new myeloma treatment, daratumumab (Darzalex®) on the NHS, after the Scottish Medicines Consortium (SMC) approved it for use.